Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route

Tripathi, Shourya; Gupta, Ujala; Ujjwal, Rewati Raman; Yadav, Awesh K.

doi:10.1080/02652048.2021.1986585

Cited by 13 publications

(6 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This comprehensive strategy provided valuable insights into the feasibility of utilizing chitosan-decorated nanostructured lipid carriers for enhanced brain targeting and therapeutic efficacy. Tripathi et al [ 65 ] addressed the challenge of brain delivery for Cinnarizine through nanostructured lipid carriers loaded into in situ gel. The research involved thorough in vitro and pharmacokinetic evaluations, establishing the augmented brain delivery of Cinnarizine as a tangible outcome of their innovative formulation strategy.…”

Section: Discussionmentioning

confidence: 99%

Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders

Agosti,

Zeppieri,

Antonietti

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Background: The blood–brain barrier (BBB) regulates brain substance entry, posing challenges for treating brain diseases. Traditional methods face limitations, leading to the exploration of non-invasive intranasal drug delivery. This approach exploits the direct nose-to-brain connection, overcoming BBB restrictions. Intranasal delivery enhances drug bioavailability, reduces dosage, and minimizes systemic side effects. Notably, lipid nanoparticles, such as solid lipid nanoparticles and nanostructured lipid carriers, offer advantages like improved stability and controlled release. Their nanoscale size facilitates efficient drug loading, enhancing solubility and bioavailability. Tailored lipid compositions enable optimal drug release, which is crucial for chronic brain diseases. This review assesses lipid nanoparticles in treating neuro-oncological and neurodegenerative conditions, providing insights for effective nose-to-brain drug delivery. Methods: A systematic search was conducted across major medical databases (PubMed, Ovid MEDLINE, and Scopus) up to 6 January 2024. The search strategy utilized relevant Medical Subject Heading (MeSH) terms and keywords related to “lipid nanoparticles”, “intranasal administration”, “neuro-oncological diseases”, and “neurodegenerative disorders”. This review consists of studies in vitro, in vivo, or ex vivo on the intranasal administration of lipid-based nanocarriers for the treatment of brain diseases. Results: Out of the initial 891 papers identified, 26 articles met the eligibility criteria after a rigorous analysis. The exclusion of 360 articles was due to reasons such as irrelevance, non-reporting selected outcomes, the article being a systematic literature review or meta-analysis, and lack of method/results details. This systematic literature review, focusing on nose-to-brain drug delivery via lipid-based nanocarriers for neuro-oncological, neurodegenerative, and other brain diseases, encompassed 60 studies. A temporal distribution analysis indicated a peak in research interest between 2018 and 2020 (28.3%), with a steady increase over time. Regarding drug categories, Alzheimer’s disease was prominent (26.7%), followed by antiblastic drugs (25.0%). Among the 65 drugs investigated, Rivastigmine, Doxorubicin, and Carmustine were the most studied (5.0%), showcasing a diverse approach to neurological disorders. Notably, solid lipid nanoparticles (SLNs) were predominant (65.0%), followed by nanostructured lipid carriers (NLCs) (28.3%), highlighting their efficacy in intranasal drug delivery. Various lipids were employed, with glyceryl monostearate being prominent (20.0%), indicating preferences in formulation. Performance assessment assays were balanced, with in vivo studies taking precedence (43.3%), emphasizing the translation of findings to complex biological systems for potential clinical applications. Conclusions: This systematic review reveals the transformative potential of intranasal lipid nanoparticles in treating brain diseases, overcoming the BBB. Positive outcomes highlight the effectiveness of SLNs and NLCs, which are promising new approaches for ailments from AD to stroke and gliomas. While celebrating progress, addressing challenges like nanoparticle toxicity is also crucial.

show abstract

Section: Discussionmentioning

confidence: 99%

Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders

Agosti,

Zeppieri,

Antonietti

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…NLCs are used for the delivery of drugs from the nose to the brain and in AD treatment associated with microglial activation [ 50 ]. The NLCs have merits over conventional dosages because of their lipophilic nature and smaller size compared to the particle size of conventional dosage forms, which helps the drug molecules easily cross the BBB [ 51 ]. The lipid matrix protects the NLCs from being degraded by enzymes and allows the active drug to reach the target site [ 52 , 53 ].…”

Section: Application Of Nanomedicines In the Management Of Alzheimer’smentioning

confidence: 99%

Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art

et al. 2023

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a deadly, progressive, and irreversible brain condition that impairs cognitive abilities. Globally, it affects 32.6 million individuals, and if no viable therapies are available by 2050, that figure might rise to 139 million. The current course of treatment enhances cognitive abilities and temporarily relieves symptoms, but it does not halt or slow the disease’s development. Additionally, treatments are primarily offered in conventional oral dosage forms, and conventional oral treatments lack brain specialization and cause adverse effects, resulting in poor patient compliance. A potential nanotechnology-based strategy can improve the bioavailability and specificity of the drug targeting in the brain. Furthermore, this review extensively summarizes the applications of nanomedicines for the effective delivery of drugs used in the management of AD. In addition, the clinical progress of nanomedicines in AD is also discussed, and the challenges facing the clinical development of nanomedicines are addressed in this article.

show abstract

“…Intranasal administration is a convenient way to cross the blood-brain barrier to target drugs towards the brain. By this noninvasive way, bypassing the BBB, presystemic metabolism may be eliminated [ 130 ]. At this point, in one study, curcumin-loaded AmyloLipid nanovesicles (ALNs) were fabricated to manage AD by inhibiting A β aggregation and A β -induced inflammation by nasal delivery.…”

Section: New Delivery Systems Used To Increase Curcumin Bioavailabilitymentioning

confidence: 99%

A New Perspective on the Treatment of Alzheimer’s Disease and Sleep Deprivation-Related Consequences: Can Curcumin Help?

Akkol

Bardakçı

Yücel

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Sleep disturbances, as well as sleep-wake rhythm disorders, are characteristic symptoms of Alzheimer’s disease (AD) that may head the other clinical signs of this neurodegenerative disease. Age-related structural and physiological changes in the brain lead to changes in sleep patterns. Conditions such as AD affect the cerebral cortex, basal forebrain, locus coeruleus, and the hypothalamus, thus changing the sleep-wake cycle. Sleep disorders likewise adversely affect the course of the disease. Since the sleep quality is important for the proper functioning of the memory, impaired sleep is associated with problems in the related areas of the brain that play a key role in learning and memory functions. In addition to synthetic drugs, utilization of medicinal plants has become popular in the treatment of neurological diseases. Curcuminoids, which are in a diarylheptanoid structure, are the main components of turmeric. Amongst them, curcumin has multiple applications in treatment regimens of various diseases such as cardiovascular diseases, obesity, cancer, inflammatory diseases, and aging. Besides, curcumin has been reported to be effective in different types of neurodegenerative diseases. Scientific studies exclusively showed that curcumin leads significant improvements in the pathological process of AD. Yet, its low solubility hence low bioavailability is the main therapeutic limitation of curcumin. Although previous studies have focused different types of advanced nanoformulations of curcumin, new approaches are needed to solve the solubility problem. This review summarizes the available scientific data, as reported by the most recent studies describing the utilization of curcumin in the treatment of AD and sleep deprivation-related consequences.

show abstract

Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route

Cited by 13 publications

References 124 publications

Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders

Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders

Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art

A New Perspective on the Treatment of Alzheimer’s Disease and Sleep Deprivation-Related Consequences: Can Curcumin Help?

Contact Info

Product

Resources

About